BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 10779814)

  • 1. [Oral granisetron solution as prophylaxis for chemotherapy-induced emesis in children: double-blind study of 2 doses].
    Mabro M; Cohn R; Zanesco L; Madon E; Hahlen K; Margueritte G; Breatnach F; Gentet JC; Plouvier é
    Bull Cancer; 2000 Mar; 87(3):259-64. PubMed ID: 10779814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
    Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
    Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
    Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
    Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation.
    Fox-Geiman MP; Fisher SG; Kiley K; Fletcher-Gonzalez D; Porter N; Stiff P
    Biol Blood Marrow Transplant; 2001; 7(11):596-603. PubMed ID: 11760147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of tropisetron and granisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
    Aksoylar S; Akman SA; Ozgenç F; Kansoy S
    Pediatr Hematol Oncol; 2001 Sep; 18(6):397-406. PubMed ID: 11554235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
    Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
    Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy.
    Berrak SG; Ozdemir N; Bakirci N; Turkkan E; Canpolat C; Beker B; Yoruk A
    Support Care Cancer; 2007 Oct; 15(10):1163-8. PubMed ID: 17372773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
    Mabro M; Granisétron PK
    Bull Cancer; 1999 Mar; 86(3):295-301. PubMed ID: 10210764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
    Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
    J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of a continuous infusion, patient-controlled antiemetic pump for children receiving emetogenic chemotherapy.
    Jones E; Koyama T; Ho RH; Kuttesch J; Shankar S; Whitlock JA; Cartwright J; Frangoul H
    Pediatr Blood Cancer; 2007 Mar; 48(3):330-2. PubMed ID: 16304666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting.
    Jordan K; Grothey A; Kegel T; Fibich C; Schöbert C
    Onkologie; 2005 Feb; 28(2):88-92. PubMed ID: 15662112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy.
    White L; Daly SA; McKenna CJ; Zhestkova N; Leal C; Breatnach F; Smelhaus V; Hung IJ; Kowalczyk J; Ninane J; Mitchell T; Haigh C
    Pediatr Hematol Oncol; 2000 Sep; 17(6):445-55. PubMed ID: 10989464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granisetron vs ondansetron for prevention of nausea and vomiting in hematopoietic stem cell transplant patients: results of a prospective, double-blind, randomized trial.
    Walsh T; Morris AK; Holle LM; Callander N; Bradshaw P; Valley AW; Clark G; Freytes CO
    Bone Marrow Transplant; 2004 Dec; 34(11):963-8. PubMed ID: 15489869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled study comparing two doses of intravenous granisetron (1 and 3 mg) for acute chemotherapy-induced nausea and vomiting in cancer patients: a non-inferiority trial.
    Yonemura M; Katsumata N; Hashimoto H; Satake S; Kaneko M; Kobayashi Y; Takashima A; Kato Y; Takeuchi M; Fujiwara Y; Yamamoto H; Hojo T
    Jpn J Clin Oncol; 2009 Jul; 39(7):443-8. PubMed ID: 19395466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
    Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
    J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy.
    Carmichael J; Harris AL
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):123-8. PubMed ID: 14634790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin. The Italian Multicenter Study Group.
    Anticancer Drugs; 1999 Jun; 10(5):465-70. PubMed ID: 10477166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy.
    Hesketh PJ; Crews JR; Cohen R; Blackburn LM; Friedman CJ
    Cancer J; 2000; 6(3):157-61. PubMed ID: 10882331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.